Johan L. Elf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johan L. Elf has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anders Gottsäter
Department of Internal Medicine, Clinical Research Unit, Lund University, Skåne University Hospital, Malmö, Sweden
2 shared publications C. Nilsson
2 shared publicationsK. Strandberg
2 shared publications- Moncef Zarrouk
Lund University, Department of Vascular Diseases, Skåne University Hospital, S-205 02 Malmö, Sweden
2 shared publications P.J. Svensson
2 shared publications- Saman Salim
Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
2 shared publications
Latest Publications
- Open Access
- 24 January 2024
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 57 (3) , 497-502
Association between changed self-rated health and the risk of venous thromboembolism in Malmö Preventive Program: a cohort study
Poor self-rated health (SRH) is associated with incident arterial cardiovascular disease in both sexes. Studies on the association between SRH and incident venous thromboembolism (VTE) show divergent results in women and no association in men. This study focuses on the association between change in SRH and incident VTE in a cohort of 11,558 men and 6682 women who underwent a baseline examination and assessment of SRH between 1974 and 1992 and a re-examination in 2002–2006. To investigate if changes in SRH over time affect the risk of incident VTE in men and women. During a follow-up time from the re-examination of more than 16 years, there was a lower risk for incident VTE among women if SRH changed from poor at baseline to very good/excellent (HR 0.46, 95% CI 0.28; 0.74) at the re-examination. Stable good SRH (good to very good/excellent at the re-examination, HR 0.60, 95% CI 0.42; 0.89), or change from good SRH at baseline into poor/fair at the re-examination (HR 0.68, 95% CI 0.51; 0.90) were all significantly associated with a reduced risk for VTE. All comparisons were done with the group with stable poor SRH. This pattern was not found among men. Regardless of a decreased or increased SRH during life, having an SRH of very good/excellent at any time point seems to be associated with a decreased risk of VTE among women.
- 24 January 2024
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 57 (3) , 497-502
Open AccessAssociation between changed self-rated health and the risk of venous thromboembolism in Malmö Preventive Program: a cohort study
Poor self-rated health (SRH) is associated with incident arterial cardiovascular disease in both sexes. Studies on the association between SRH and incident venous thromboembolism (VTE) show divergent results in women and no association in men. This study focuses on the association between change in SRH and incident VTE in a cohort of 11,558 men and 6682 women who underwent a baseline examination and assessment of SRH between 1974 and 1992 and a re-examination in 2002–2006. To investigate if changes in SRH over time affect the risk of incident VTE in men and women. During a follow-up time from the re-examination of more than 16 years, there was a lower risk for incident VTE among women if SRH changed from poor at baseline to very good/excellent (HR 0.46, 95% CI 0.28; 0.74) at the re-examination. Stable good SRH (good to very good/excellent at the re-examination, HR 0.60, 95% CI 0.42; 0.89), or change from good SRH at baseline into poor/fair at the re-examination (HR 0.68, 95% CI 0.51; 0.90) were all significantly associated with a reduced risk for VTE. All comparisons were done with the group with stable poor SRH. This pattern was not found among men. Regardless of a decreased or increased SRH during life, having an SRH of very good/excellent at any time point seems to be associated with a decreased risk of VTE among women.
- Open Access
- 1 August 2018
- Published by AME Publishing Company in AME Medical Journal
- Vol. 3, 90
Thrombophilia testing in mesenteric venous thrombosis, when to screen
- 1 August 2018
- Published by AME Publishing Company in AME Medical Journal
- Vol. 3, 90
Open AccessThrombophilia testing in mesenteric venous thrombosis, when to screen
- Open Access
- 5 January 2018
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 45 (2) , 319-324
Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism
Anticoagulant treatment of acute pulmonary embolism (PE) has traditionally been hospital-based. The lesser need for monitoring with the increasingly used direct acting oral anticoagulants (DOAC) in comparison to warfarin potentially facilitates outpatient treatment of PE with these drugs. This study aimed to evaluate efficacy and safety of outpatient treatment of PE with DOAC. We extracted data from the Swedish quality registry for patients on oral anticoagulation (AuriculA) for all 245 patients in the southernmost hospital region in Sweden (1.3 million inhabitants) selected for outpatient treatment with of PE with DOAC during 2013–2015. Comorbidites, risk factors, and simplified pulmonary embolism severity index were evaluated at baseline, and death, recurrent venous thromboembolism (VTE), and bleeding was recorded during 6 months of follow-up. Outpatient treatment was defined as discharge from the emergency department within 24 h. During 6 months of follow-up, one patient died during DOAC therapy, the cause of death was unrelated to VTE. No VTE recurrences occured, whereas, one patient experienced major bleeding, and five patients experienced minor bleedings. Outpatient treatment of PE with DOAC is efficient and safe in selected patients.
- 5 January 2018
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 45 (2) , 319-324
Open AccessEfficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism
Anticoagulant treatment of acute pulmonary embolism (PE) has traditionally been hospital-based. The lesser need for monitoring with the increasingly used direct acting oral anticoagulants (DOAC) in comparison to warfarin potentially facilitates outpatient treatment of PE with these drugs. This study aimed to evaluate efficacy and safety of outpatient treatment of PE with DOAC. We extracted data from the Swedish quality registry for patients on oral anticoagulation (AuriculA) for all 245 patients in the southernmost hospital region in Sweden (1.3 million inhabitants) selected for outpatient treatment with of PE with DOAC during 2013–2015. Comorbidites, risk factors, and simplified pulmonary embolism severity index were evaluated at baseline, and death, recurrent venous thromboembolism (VTE), and bleeding was recorded during 6 months of follow-up. Outpatient treatment was defined as discharge from the emergency department within 24 h. During 6 months of follow-up, one patient died during DOAC therapy, the cause of death was unrelated to VTE. No VTE recurrences occured, whereas, one patient experienced major bleeding, and five patients experienced minor bleedings. Outpatient treatment of PE with DOAC is efficient and safe in selected patients.
- Open Access
- 3 October 2017
- Published by Springer Nature in Thrombosis Journal
- Vol. 15 (1) , 1-4
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis
Upper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in the arm. The incidence of secondary UEDVT is increasing due to widespread use of central venous catheters in patients with cancer and other chronic diseases. The safety and efficacy of using new direct acting oral anti coagulants (DOAC) in the treatment of UEDVT has not been systematically evaluated. Our aims were to evaulate efficacy, safety, and risk of recurrence of venous thromboembolism (VTE) during DOAC treatment in UEDVT patients. Data from the Swedish national anticoagulation registry (AuriculA) was retrospectively evaluated for all 55 patients (27 men aged 23–86 years, and 28 women aged 18–75 years) treated with DOAC because of UEDVT between 2012 and 2015 in the southernmost hospital region of Sweden with 1.3 million inhabitants in 2016. Patients were followed for 6 months. During 6 months after institution of DOAC treatment there was one recurrence (2%) of DVT during treatment and two (4%) recurrences after cessation of treatment. No patient died, whereas one (2%) suffered a clinically relevant nonmajor bleeding. DOAC can be used in the treatment of UEDVT patients with acceptable efficacy and safety.
- 3 October 2017
- Published by Springer Nature in Thrombosis Journal
- Vol. 15 (1) , 1-4
Open AccessTreatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis
Upper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in the arm. The incidence of secondary UEDVT is increasing due to widespread use of central venous catheters in patients with cancer and other chronic diseases. The safety and efficacy of using new direct acting oral anti coagulants (DOAC) in the treatment of UEDVT has not been systematically evaluated. Our aims were to evaulate efficacy, safety, and risk of recurrence of venous thromboembolism (VTE) during DOAC treatment in UEDVT patients. Data from the Swedish national anticoagulation registry (AuriculA) was retrospectively evaluated for all 55 patients (27 men aged 23–86 years, and 28 women aged 18–75 years) treated with DOAC because of UEDVT between 2012 and 2015 in the southernmost hospital region of Sweden with 1.3 million inhabitants in 2016. Patients were followed for 6 months. During 6 months after institution of DOAC treatment there was one recurrence (2%) of DVT during treatment and two (4%) recurrences after cessation of treatment. No patient died, whereas one (2%) suffered a clinically relevant nonmajor bleeding. DOAC can be used in the treatment of UEDVT patients with acceptable efficacy and safety.
- 1 February 2017
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 31 (1) , 39-48
Testing for thrombophilia in mesenteric venous thrombosis – Retrospective original study and systematic review
- 1 February 2017
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 31 (1) , 39-48
Testing for thrombophilia in mesenteric venous thrombosis – Retrospective original study and systematic review
- 19 June 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 39 (2) , 166-172
Home treatment of patients with small to medium sized acute pulmonary embolism
Most patients with acute pulmonary embolism (PE) are still treated as inpatients. This is a retrospective cohort study of patients with acute PE, diagnosed using V/P SPECT between 2007 and 2011. Patients were treated at home if they were hemodynamically stable, did not require oxygen or parenteral analgetics, had no contraindications to anticoagulant treatment and V/P SPECT showed an extension of the PE of less than 40 %. The aim of the study was to evaluate the efficacy and safety of home treatment with our algorithm. During the study period 416 outpatients were diagnosed with acute symptomatic PE of whom in total 260 (62.5 %) were discharged home from the emergency unit and another 47 (11 %) within 24 h from admission. During 3 months follow-up one (0.3 %) patient had a recurrent thrombotic event. Eleven (3.6 %) patients had a major or clinically relevant bleed and the overall mortality was 2 % (n = 6). There were no PE-related mortality. Home treatment should be considered and is safe in the majority of hemodynamically stable outpatients with small to medium size PE, quantified using V/P SPECT.
- 19 June 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 39 (2) , 166-172
Home treatment of patients with small to medium sized acute pulmonary embolism
Most patients with acute pulmonary embolism (PE) are still treated as inpatients. This is a retrospective cohort study of patients with acute PE, diagnosed using V/P SPECT between 2007 and 2011. Patients were treated at home if they were hemodynamically stable, did not require oxygen or parenteral analgetics, had no contraindications to anticoagulant treatment and V/P SPECT showed an extension of the PE of less than 40 %. The aim of the study was to evaluate the efficacy and safety of home treatment with our algorithm. During the study period 416 outpatients were diagnosed with acute symptomatic PE of whom in total 260 (62.5 %) were discharged home from the emergency unit and another 47 (11 %) within 24 h from admission. During 3 months follow-up one (0.3 %) patient had a recurrent thrombotic event. Eleven (3.6 %) patients had a major or clinically relevant bleed and the overall mortality was 2 % (n = 6). There were no PE-related mortality. Home treatment should be considered and is safe in the majority of hemodynamically stable outpatients with small to medium size PE, quantified using V/P SPECT.
- 1 December 2009
- Published by Elsevier in Thrombosis Research
- Vol. 124 (6) , 701-705
Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis
- 1 December 2009
- Published by Elsevier in Thrombosis Research
- Vol. 124 (6) , 701-705
Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis
- 24 November 2009
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 29 (4) , 465-470
The diagnostic performance of APC–PCI complex determination compared to d-dimer in the diagnosis of deep vein thrombosis
D-dimer testing is widely used as part of the diagnostic algorithm for the exclusion of deep vein thrombosis (DVT) but is considered of limited in value for ruling DVT in. Since d-dimers are poorly defined, there is no standardization of the assays and this makes reliable comparisons between clinical studies difficult. We report on a performance evaluation of a new marker of activated coagulation (Activated Protein-C in complex with Protein-C inhibitor, APC–PCI complex) compared to two quantitative d-dimer assays (Vidas® d-dimer Exclusion™and Autodimer®). The post-hoc comparison was made on 350 frozen plasma samples from consecutive outpatients suspected of DVT in a multicenter management study including clinical probability score, d-dimer testing, venous ultrasound and contrast venography as part of the diagnostic algorithm. Results: The APC–PCI complex performed inferior to the d-dimer assays in terms of sensitivity: 74 vs. >93%, negative predictive value: 91 vs. >96% and area under the curve: 0.82 vs. 0.9, but showed a significantly higher specificity: 80 vs. 40–60%. Specificity for the APC–PCI complex did not decrease with higher clinical probability score and the positive predictive value was significantly higher than that of the d-dimer assays in the intermediate/high probability cohort (66 vs. 90% in up to 20% of the patients which indicates important clinical implications. However, for the exclusion of DVT at the pre-specified cut-off level, the APC–PCI complex perform inferior to the d-dimer assays in this study.
- 24 November 2009
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 29 (4) , 465-470
The diagnostic performance of APC–PCI complex determination compared to d-dimer in the diagnosis of deep vein thrombosis
D-dimer testing is widely used as part of the diagnostic algorithm for the exclusion of deep vein thrombosis (DVT) but is considered of limited in value for ruling DVT in. Since d-dimers are poorly defined, there is no standardization of the assays and this makes reliable comparisons between clinical studies difficult. We report on a performance evaluation of a new marker of activated coagulation (Activated Protein-C in complex with Protein-C inhibitor, APC–PCI complex) compared to two quantitative d-dimer assays (Vidas® d-dimer Exclusion™and Autodimer®). The post-hoc comparison was made on 350 frozen plasma samples from consecutive outpatients suspected of DVT in a multicenter management study including clinical probability score, d-dimer testing, venous ultrasound and contrast venography as part of the diagnostic algorithm. Results: The APC–PCI complex performed inferior to the d-dimer assays in terms of sensitivity: 74 vs. >93%, negative predictive value: 91 vs. >96% and area under the curve: 0.82 vs. 0.9, but showed a significantly higher specificity: 80 vs. 40–60%. Specificity for the APC–PCI complex did not decrease with higher clinical probability score and the positive predictive value was significantly higher than that of the d-dimer assays in the intermediate/high probability cohort (66 vs. 90% in up to 20% of the patients which indicates important clinical implications. However, for the exclusion of DVT at the pre-specified cut-off level, the APC–PCI complex perform inferior to the d-dimer assays in this study.
- 31 August 2009
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 50 (2) , 467
Clinical Probability Assessment and D-Dimer Determination in Patients with Suspected Deep Vein Thrombosis, a Prospective Multi-Center Management Study
- 31 August 2009
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 50 (2) , 467
Clinical Probability Assessment and D-Dimer Determination in Patients with Suspected Deep Vein Thrombosis, a Prospective Multi-Center Management Study
- 1 February 2009
- Published by Elsevier in Thrombosis Research
- Vol. 123 (4) , 612-616
Clinical probability assessment and D-dimer determination in patients with suspected deep vein thrombosis, a prospective multicenter management study
- 1 February 2009
- Published by Elsevier in Thrombosis Research
- Vol. 123 (4) , 612-616
Clinical probability assessment and D-dimer determination in patients with suspected deep vein thrombosis, a prospective multicenter management study